230 related articles for article (PubMed ID: 36484006)
1. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.
Zhao J; Zhang Y; Qin S; Zou B; Wang Y
J Cancer; 2022; 13(14):3539-3553. PubMed ID: 36484006
[No Abstract] [Full Text] [Related]
2. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Mustafayev K; Mallet V; Torres HA
J Immunother Precis Oncol; 2024 May; 7(2):111-121. PubMed ID: 38721408
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Xia Z; Zhang J; Chen W; Zhou H; Du D; Zhu K; Chen H; Meng J; Yang J
Infect Dis Poverty; 2023 Sep; 12(1):87. PubMed ID: 37736699
[TBL] [Abstract][Full Text] [Related]
4. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.
Ding ZN; Meng GX; Xue JS; Yan LJ; Liu H; Yan YC; Chen ZQ; Hong JG; Wang DX; Dong ZR; Li T
J Cancer Res Clin Oncol; 2023 May; 149(5):1993-2008. PubMed ID: 35767193
[TBL] [Abstract][Full Text] [Related]
7. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
Yoo S; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Yoo C; Ryoo BY; Choi J
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):898-907. PubMed ID: 34182151
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
[TBL] [Abstract][Full Text] [Related]
9. Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection.
Hagiwara S; Nishida N; Ida H; Ueshima K; Minami Y; Takita M; Aoki T; Morita M; Chishina H; Komeda Y; Yoshida A; Hayashi H; Nakagawa K; Kudo M
Hepatol Res; 2022 Sep; 52(9):754-761. PubMed ID: 35635496
[TBL] [Abstract][Full Text] [Related]
10. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
Front Immunol; 2022; 13():892618. PubMed ID: 35711409
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
[TBL] [Abstract][Full Text] [Related]
12. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review.
Kuo L; Kuwelker S; Tsai E
Ann Palliat Med; 2023 Nov; 12(6):1275-1294. PubMed ID: 37731304
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey.
Tagliamento M; Remon J; Giaj Levra M; De Maria A; Bironzo P; Besse B; Novello S; Mezquita L
JTO Clin Res Rep; 2023 Jan; 4(1):100446. PubMed ID: 36687558
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.
Cook MR; Kim C
JAMA Oncol; 2019 Jul; 5(7):1049-1054. PubMed ID: 30730549
[TBL] [Abstract][Full Text] [Related]
15. HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition.
Baumert LS; Shih AR; Chung RT
Med; 2024 Feb; 5(2):126-131.e1. PubMed ID: 38340708
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
Pertejo-Fernandez A; Ricciuti B; Hammond SP; Marty FM; Recondo G; Rangachari D; Costa DB; Awad MM
Lung Cancer; 2020 Jul; 145():181-185. PubMed ID: 32423643
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
19. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?
De Keukeleire SJ; Vermassen T; Nezhad ZM; Kerre T; Kruse V; Vlierberghe HV; Vermaelen K; Rottey S
Immunotherapy; 2021 Apr; 13(5):409-418. PubMed ID: 33487052
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
Chan GH; Gwee YX; Low JL; Huang Y; Chan ZY; Choo JR; Ngoi NY; LE Ang Y; Muthu V; Chong WQ; Wong A; Soo RA
Lung Cancer; 2020 Aug; 146():145-153. PubMed ID: 32540557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
